Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Environmental and Public Health|June 8, 2011
Persistent organic pollutants in serum and several different fat compartments in humansGeorge W Yu, John Laseter, Charles Mylander
Hormone Molecular Biology and Clinical Investigation|December 2, 2014
Circulating levels of gonadotropins before and after prostate ablation in cancer patientsGeorge Yu, Charles Mylander, Abdulmaged Traish, et al.
The Breast Journal|May 25, 2013
Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?Meghan Milburn, Martin Rosman, Charles Mylander, et al.
Annals of Surgical Oncology|July 31, 2015
Normal Axillary Ultrasound Excludes Heavy Nodal Disease Burden in Patients with Breast CancerRubie Sue Jackson, Charles Mylander, Martin Rosman, et al.
Plastic and Reconstructive Surgery. Global Open|July 31, 2024
Complications after Oncoplastic Breast Reduction and Impact on Time to Adjuvant TherapyMicaela Moen, Tripp Holton, Angelina Phung, et al.
Annals of Surgical Oncology|February 7, 2020
Ultrasound-Based Nomogram Identifies Breast Cancer Patients Unlikely to Harbor Axillary Metastasis: Towards Selective Omission of Sentinel Lymph Node BiopsyHanh-Tam Tran, Daina Pack, Charles Mylander, et al.
Plastic and Reconstructive Surgery. Global Open|September 28, 2022
Outcomes of Margin Reexcision after Oncoplastic Breast ReductionTasha A Martin, Salman Choudhry, Luther H Holton, et al.
Hematology/Oncology and Stem Cell Therapy|June 26, 2021
Recurrence Score Testing Does not Appear to Benefit Patients With Grade 1, Progesterone Receptor-Positive Breast Cancers: An Opportunity to Eliminate Overtreatment and Decrease Testing CostsUdai S Sibia, Thomas J Sanders, Charles Mylander, et al.
Hematology/Oncology and Stem Cell Therapy|June 26, 2023
OncotypeDX Testing Does Not Benefit Patients with Estrogen and Progesterone Receptor Positive Grade 1 Breast Cancers: A TAILORx Validated StudyUdai S Sibia, Charles Mylander, Tasha Martin, et al.
Clinical Breast Cancer|May 19, 2021
The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?Elaine Lee, Carol Tweed, Charles Mylander, et al.
Pageof 2